Literature DB >> 4639404

Antidepressants and liver disease.

M H Morgan, A E Read.   

Abstract

Patients with cirrhosis were found to be extremely sensitive to tranylcypromine, and the use of this drug for the treatment of depression in such patients is contraindicated. Amitriptyline has a wider margin of safety in such patients, but caution is necessary when the higher therapeutic doses are prescribed.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4639404      PMCID: PMC1412380          DOI: 10.1136/gut.13.9.697

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  Amines in blood and urine in relation to liver disease.

Authors:  A M ASATOOR; D N KERR
Journal:  Clin Chim Acta       Date:  1961-03       Impact factor: 3.786

2.  INTERACTION BETWEEN CHEESE AND MONOAMINE-OXIDASE INHIBITORS IN RATS AND CATS.

Authors:  B BLACKWELL; E MARLEY
Journal:  Lancet       Date:  1964-03-07       Impact factor: 79.321

3.  Effect of amitriptyline on the EEG.

Authors:  D L WINFIELD; G H AIVAZIAN
Journal:  Dis Nerv Syst       Date:  1962-09

4.  Quantitative electroencephalography in man as a measure of CNS stimulation.

Authors:  L GOLDSTEIN; H B MURPHREE; C C PFEIFFER
Journal:  Ann N Y Acad Sci       Date:  1963-07-08       Impact factor: 5.691

5.  The effect of the amine oxidase inhibitor marsilid on ammonium metabolism in liver disease.

Authors:  A M DAWSON; S SHERLOCK
Journal:  Clin Sci       Date:  1958-11       Impact factor: 6.124

6.  Methionine toxicity in liver disease and its prevention by chlortetracycline.

Authors:  E A PHEAR; B RUEBNER; S SHERLOCK; W H SUMMERSKILL
Journal:  Clin Sci       Date:  1956-02       Impact factor: 6.124

7.  False neurotransmitters and hepatic failure.

Authors:  J E Fischer; R J Baldessarini
Journal:  Lancet       Date:  1971-07-10       Impact factor: 79.321

8.  Encephalopathy after portacaval anastomosis.

Authors:  A E Read; C F McCarthy; A B Ajdukiewicz; G J Brown
Journal:  Lancet       Date:  1968-11-09       Impact factor: 79.321

9.  Iatrogenic epilepsy due to antidepressant drugs.

Authors:  V Dallos; K Heathfield
Journal:  Br Med J       Date:  1969-10-11

10.  Effects of chlorpromazine in patients with hepatic disease.

Authors:  A E Read; J Laidlaw; C F McCarthy
Journal:  Br Med J       Date:  1969-08-30
View more
  9 in total

1.  Sedation in liver disease.

Authors: 
Journal:  Br Med J       Date:  1977-05-14

Review 2.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

3.  Safe prescribing in liver disease.

Authors: 
Journal:  Br Med J       Date:  1973-04-28

4.  Intravenous administration of diazepam in patients with chronic liver disease.

Authors:  R A Branch; M H Morgan; J James; A E Read
Journal:  Gut       Date:  1976-12       Impact factor: 23.059

5.  Benzodiazepine-associated hepatic encephalopathy significantly increased healthcare utilization and medical costs of Chinese cirrhotic patients: 7-year experience.

Authors:  Pei-Chang Lee; Ying-Ying Yang; Ming-Wei Lin; Ming-Chih Hou; Chien-Sheng Huang; Kuei-Chuan Lee; Ying-Wen Wang; Yun-Cheng Hsieh; Yi-Hsiang Huang; Chi-Jen Chu; Han-Chieh Lin
Journal:  Dig Dis Sci       Date:  2014-01-31       Impact factor: 3.199

6.  Neuropsychologic effects of diazepam related to single dose kinetics and liver function.

Authors:  J Hendel; P Elsass; P B Andreasen; E Gymoese; E F Hvidberg
Journal:  Psychopharmacology (Berl)       Date:  1976-07-09       Impact factor: 4.530

Review 7.  Drug prescribing in hepatobiliary disease.

Authors:  R K Roberts; P V Desmond; S Schenker
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

Review 8.  Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.

Authors:  Chantal Schlatter; Sabin S Egger; Lydia Tchambaz; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 9.  Drug administration in chronic liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.228

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.